Sanofi is preparing a new vaccine and biopharmaceutical manufacturing facility in Singapore, located at Tuas Biomedical Park, Bloomberg reported Nov. 27.
The plant, dubbed Modulus, represents an investment of approximately $600 million and is set to be fully operational by mid-2026.
The facility is designed to produce up to four vaccines or biopharmaceuticals simultaneously and can be reconfigured within days, compared to the months or years typically required for traditional plants.
The expansion supports Singapore's efforts to strengthen its vaccine manufacturing capacity.